Congress Navigator
All HCPs
04

HCP 04

Medical Oncologist · Germany · Senior consultant

Illustrative synthetic data for prototype demonstration — not real clinical findings.

Discussion summary

Strong advocate for the mechanism; views the endpoint as clinically meaningful and readily adoptable.

Key themes

Magnitude of benefitSequencing

Pre / post perception

Overall perception shift

Pre-congress vs post-congress

3 improved · 1 declined

Perception of clinical efficacy

Low
Very low
-1

Confidence in the evidence

Neutral
Neutral
0

Safety / tolerability perception

Positive
Very positive
+1

Likelihood to prescribe

Low
Neutral
+1

Familiarity with treatment

Neutral
Neutral
0

Competitive perception

Positive
Very positive
+1

Illustrative synthetic measures. Movement is shown as an observed pre/post shift, not a causal effect of the congress.

KBQs discussed

Position against each predefined question

Clinical significance of the primary endpoint

What is the expert consensus regarding the clinical significance of the study’s primary endpoint results?

Supportive
“What matters is that the benefit looks clinically meaningful, not just statistically significant.”
See aggregated KBQ finding

Safety, tolerability and willingness to prescribe

How do HCP perceptions of the trial’s safety and tolerability profile impact their willingness to adopt and prescribe the treatment?

High willingness
“Nothing here is unfamiliar; managing these events is part of routine class experience.”
See aggregated KBQ finding

Use in node-positive populations

What is the clinical consensus among HCPs regarding the use of CDK4/6 inhibitors in node-positive patient populations?

Favourable
“These higher-risk patients are exactly who I would prioritise.”
See aggregated KBQ finding

Sequencing after adjuvant recurrence

How do clinicians approach treatment sequencing following recurrence on an adjuvant CDK4/6 inhibitor?

Switch mechanism
“If they have progressed on the class, continuing it rarely makes sense to me.”
See aggregated KBQ finding

Compelling nature of the primary endpoint

How compelling are the primary endpoint findings in driving prospective prescribers to select this treatment over existing options?

Compelling
“The data feel mature and robust enough for me to act on confidently.”
See aggregated KBQ finding

Perception of safety and tolerability

How do experts perceive the safety and tolerability profile demonstrated in the trial?

Favourable
“No new signal emerged, which is reassuring.”
See aggregated KBQ finding